Clarity Pharmaceuticals Completes Capital Raise

Clarity Pharmaceuticals (ASX: CU6), a clinical stage company specializing in radiopharmaceuticals, announced the successful closure of its fully underwritten Retail Entitlement Offer, part of a broader capital raise initiative that included both institutional and retail components. The company raised approximately AU$10.8 million from the retail offer and AU$121 million overall.

The funds are earmarked for advancing their portfolio of therapeutic and diagnostic products aimed at improving cancer treatments for both children and adults. With a strong financial base now exceeding AU$150 million, Clarity aims to enhance its position in the burgeoning field of radiopharmaceuticals. New shares from the retail offer are expected to be issued by the end of April 2024, following the underwriting process managed by Bell Potter and Wilsons Corporate Finance.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com